. 2009 May 18;157(5):781–795. doi: 10.1111/j.1476-5381.2009.00263.x

Table 2.

Effects of increasing concentrations of BAY 58-2667 on sGC protein levels under normal and haem-oxidizing conditions in endothelial cells

ECs	α₁ sGC		β₁ sGC
BAY 58-2667	ODQ (10 µmol·L⁻¹)		ODQ (10 µmol·L⁻¹)
[µmol·L⁻¹]	−	+	−	+
–	100	58 ± 4^***	100	46 ± 3^***
0.01	108 ± 3^***^†††	60 ± 8^***^###	106 ± 5^***^†††	53 ± 5^***^###
0.1	99 ± 11††	64 ± 15^***	111 ± 11^**^†††	74 ± 9^***^†††^#
1	100 ± 9^†††	92 ± 9^**^††	138 ± 13^***^†††	129 ± 17^***^†††
10	103 ± 9^†††	122 ± 12^***^†††	162 ± 24^***^†††	163 ± 22^***^†††

Values are expressed as % control (no ODQ or BAY 58-2667) and are means ± SEM of 4–29 independent experiments.

^**

P < 0.01,

^***

P < 0.005: Student's t-test (indicated sample vs. control);

^††

P < 0.01,

^†††

P < 0.005: Student's t-test (indicated sample vs. ODQ treated control);

P < 0.05,

^###

P < 0.005: Student's t-test (substance treatment vs. substance plus ODQ treatment).

BAY 58-2667, 4-[((4-carboxybutyl){2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl[benzoic]acid; cGMP, cyclic guanosine monophosphate; EC, endothelial cell; ODQ, 1H-(1,2,4)-oxadiazolo[4,3-a]quinoxalin-1-one; SEM, standard error of the mean; sGC, soluble guanylyl cyclase.